CUP40PPBJEV3

1AP7 Rec'd PCT/PTO 1 8-15 5-9 (Re-20106)
Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				ATTORNEY'S DOCKET NUMBER				
			THE UNITED STATES	PC32199A				
DESIGNATED/ELECTED OFFICE (DO/EO/U CONCERNING A SUBMISSION UNDER 35 U.S.				U.S. APPLICATION NO. (If known, see-37 CFR 1.5)				
V.INTERNATIONAL APPLICATION NO. PCT/IB2005/000610			INTERNATIONAL FILING DATE 03/04/2005	PRIORITY DATE CLAIMED 03/17/2004				
	F INVEN							
			T TESTICULAR BVDV INFECTI	ON				
APPLICANT(S) FOR DO/EO/US PFIZER PRODUCTS INC. and MICHAEL A. ELLSWORTH, et al.								
Applicant	herewith	submits to the United St	ates Designated/Elected Office (DO/	EO/US) the following items and other information:				
1.	$\boxtimes$	This is a FIRST submis	This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.					
2.		This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a submission under 35 U.S.C. 371.						
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.						
4.	$\boxtimes$	The US has been elect	ed (Article 31).					
5.	$\boxtimes$							
	A copy o		ation as filed (35 U.S.C. 371(c)(2))					
	a.		ereto (required only if not communica					
	b.	=	mmunicated by the International Bure					
	c.	_		United States Receiving Office (RO/US).				
6.	Ш	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).						
	a.	is attached hereto.						
	b.	has been previously submitted under 35 U.S.C. 154(d)(4).						
.7.	Ш	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).						
	a.	are attached hereto (required only if not communicated by the International Bureau).						
	b.	have been communicated by the International Bureau.						
	c.	have not be	have not been made; however, the time limit for making such amendments has NOT expired.					
	d.	have not bee	en made and will not be made.					
8.	Ц	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).						
9.	Ц	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).						
10.		An English language tr 36 (35 U.S.C. 371(c)(5		national Preliminary Examination Report under PCT Article				
Items 11	l to 20 be	low concern document	t(s) or information included:					
11.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.						
12.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.						
13	X	A preliminary amendment.						
14	$\boxtimes$	An Application Data Sheet under 37 CFR 1.76.						
15.		A substitute specification. 16. A power of attorney and/or change of address letter.						
16.		A power of attorney and/or change of address letter						
17.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.						
18.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).						

A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Form PTO-1390 (Rev. 07-2005)

Form PTO-1390 (Rev. 07-2005)

## IAP16 Rec'd PCT/PTO 18 SEP 2006

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPEICATION	NO. (if known see 37 CFR 93134	1.5) INTERNATIONAL FILING DATE 03/04/2005	ATTO	ORNEY'S DOCKE PC32199/		
Other items or information: International Search Report, Written Opinion, International Preliminary Report on Patentability, Recorded Assignment						
The Following Fees	have been submitted			CALCULATIONS	PTO USE ONLY	
21. Basi	c national fee (37 CFR 1.492	2(a))	\$300	\$ 300.00		
22. Exam If the written opinion by IPEA/I All other situations	\$ 200.00					
23. Significant with the written opinion by IPEA/I Search fee (37 CFF International Search previous) All other situations	\$ 400.00					
	Total o	f 21, 22 and 23 =		\$900.00		
Additional sequence The fee is						
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round <b>up</b> to a whole number)	RATE	\$		
28-100 =	0/50=	0	x \$250	\$0		
Surcharge of \$130. after the date of cor						
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$		
Total claims	<del></del>	0	x \$50	\$0		
Independent claims		Ja.	x \$200 + \$360	\$0 \$0		
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360  TOTAL OF ABOVE CALCULATIONS =						
		\$900.00				
Applicant	1-1					
	\$900.00					
Processing fee of \$ claimed priority date						
	900.00					
Fee for recording the an appropriate cover						
	900.00					
1				Amount to be refunded:	\$	
				Amount to be charged	\$ 900.00	

# IAP16 Rec'd PCT/PTO 18-SEP 2006 10/593134

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

		Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.			
a.		A check in the amount of \$ to cover the above fees ins enclosed.			
b	$\boxtimes$	Please charge my Deposit Account No. 21-0718 in the amount of \$900.00 to cover the above fees			
		A duplicate copy of this sheet is enclosed.			
Ç.	$\boxtimes$	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>21-0718</u> . A duplicate copy of this sheet is enclosed.			
d.		Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.			
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the international Application to pending status.					
Timothy J Pfizer Inc. 7000 Porta	J. Gumblete				

#### **Application Information**

Application Type::

Regular

Subject Matter::

Utility

Title::

METHOD OF VACCINATION AGAINST TESTICULAR BVDV

INFECTION

Attorney Docket Number::

PC32199A

Suggested Drawing Figure::

Total Drawing Sheets::

1

#### **Inventor Information**

Inventor Authority Type::

**INVENTOR** 

Primary Citizenship Country::

US

Given Name::

Michael A.

Family Name::

Ellsworth

City of Residence::

Lincoln

State or Prov of Residence::

Nebraska

Country of Residence::

US

Street::

5510 Thistle Circle

City::

Lincoln

State or Province::

Nebraska

Postal or Zip Code::

68516

Inventor Authority Type::

**INVENTOR** 

Primary Citizenship Country::

US

Given Name::

Cassius M.

Family Name::

Tucker

City of Residence::

Kalamazoo

State or Prov of Residence::

Michigan

Country of Residence::

US

Street::

2140 Waite Avenue

City::

Kalamazoo

State or Province::

Michigan

Postal or Zip Code::

49008

### **Application Data Sheet**

**Correspondence Information** 

Correspondence Customer Number:: 25533

Representative Information

Representative Customer Number:: 25533

**Assignee Information** 

Assignee Name:: Pfizer Inc.

**Domestic Priority Information** 

Application:: Continuity Type:: Parent Application:: Parent Filing Date::

This application National Stage of PCT/I2005/000610 03/04/2005